EOM Pharmaceuticals Holdings, Inc. (IMUC)
EOM Pharmaceuticals Holdings, Inc.
136 Summit Avenue
Montvale, NJ 07645
United States
201 351 0605
https://www.eompharma.com
Sector(es): Healthcare
Industria: Biotechnology
Empleados a tiempo completo: 3
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Dr. Irach B. Taraporewala B.S., M.S., Ph.D. | CEO, President & Director | 265.65k | N/D | 1956 |
| Mr. Wayne I. Danson CPA | CFO & Treasurer | 150k | N/D | 1954 |
| Mr. Eli Goldberger | Founder, Chairman & COO | N/D | N/D | 1990 |
| Dr. Shalom Z. Hirschman M.D. | Co-Founder, Chief Scientific Officer & Medical Director | N/D | N/D | 1936 |
Descripción
Immunocellular Therapeutics, Ltd., a clinical-stage pharmaceutical company, focuses on the development of therapeutics and delivery technologies for the treatment of inflammatory conditions and ocular diseases. Its lead clinical asset is EOM613 solution, a peptide nucleic-acid solution with anti-inflammatory and pro-inflammatory effects on cytokines and chemokines for the treatment of cancer cachexia and rheumatoid arthritis. The company also develops EOM 147, an investigational, broad-spectrum aminosterol with an intracellular mechanism for the treatment of chronic and debilitating retinal diseases. Immunocellular Therapeutics, Ltd. was founded in 2020 and is headquartered in Montvale, New Jersey.
Gestión corporativa
La calificación ISS Governance QuickScore de EOM Pharmaceuticals Holdings, Inc. a partir del N/D es N/D. Las puntuaciones principales son Auditoría: N/D; Junta: N/D; Derechos del accionista: N/D; Compensación: N/D.
